


IN THE CLAIMS:

Please amend Claims 1-7 and 13, by replacing them with the following Rewritten Claims. A copy of the Marked-up Claims is attached for the Examiner's convenience.


Rewritten Claims

1. A pharmaceutical composition comprising a compound of Formula I,



wherein

R¹ is selected from alkyl; aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with a hydroxyloweralkyl; benzimidaz-2-yl;



wherein R⁴ is phenyl optionally monosubstituted or disubstituted with a substituent selected from loweralkyl and halo; phenyl optionally monosubstituted or disubstituted with a substituent selected from amino, loweralkoxy, hydroxy and loweralkyl; NHCH₂CH₂OX wherein X represents an *in vivo* hydrolyzable ester; and C₂-C₄ alkyl-(R⁵)(R⁶) wherein one of R⁵ and R⁶ is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

A
CONT.

R² and R³ are independently selected from H, NO₂, halo, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both R² and R³ are not both hydrogen.

3. A pharmaceutical composition according to claim 2, wherein R¹ is selected from aryl-loweralkyl; loweralkyl-carbonate; amino monosubstituted or disubstituted with hydroxyloweralkyl; benzimidaz-2-yl; NHCH₂CH₂OX wherein X represents an *in vivo* hydrolyzable ester; and C₂-C₄ alkyl-(R⁵)(R⁶) wherein one of R⁵ and R⁶ is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

R² and R³ are independently selected from H, NO₂, di(loweralkyl)amino, loweralkyl and phenyl-S-, with the proviso that both R² and R³ are not both hydrogen.

4. A pharmaceutical composition according to claim 3, wherein R¹ is selected from amino monosubstituted or disubstituted with hydroxyloweralkyl; NHCH₂CH₂OX wherein X represents an *in vivo* hydrolyzable ester; and C₂-C₄ alkyl-(R⁵)(R⁶) wherein one of R⁵ and R⁶ is selected from H and loweralkyl and the other is selected from carboxy, carboxy-loweralkyl and loweralkoxy-carbonyl; and

A1
cont

R² and R³ are independently selected from H, loweralkyl and NO₂, with the proviso that both R² and R³ are not both hydrogen.

5. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

2-{2-(4-Methylphenylsulphonamido)phenyl}-6-(N,N-dimethylamino)-naphthalimide;

N-Octyl-5-nitronaphthalimide;

2-{2-(4-Methylbenzylsulphonamido)-4,5-dichlorophenyl}naphthalimide;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline;

Sch B2
1,3-Dioxo-2-{4,5-dimethyl-2-(4-methylphenylsulphonamido)phenyl}-

1,2,3,4-tetrahydrobenzo[i]isoquinoline;

3-Methyl-3-(1,3-dioxo-5-nitro(1H,3H)benz[de]isoquinolyl)butyric acid methylester;

N-(4-Ethoxyphenyl)-5-nitronaphthalimide;

Ethyl-5-nitro-1,3-dioxo-1H-benz[de]isoquinoline-2-3H-acetate;

Naphthalic acid-N,N'-diimide;

5-Amino-N-butyl naphthalimide;

1,3-Dioxo-5-nitro- η -propylmorpholino-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

N-(1,3-Dioxo-6-phenylmercapto-1,2,3,4-tetrahydrobenzo[i]isoquinoline)-

aminoethanol

A
cont.

6. A pharmaceutical composition according to claim 2 wherein the compound of Formula I is selected from the group consisting of:

N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol;

N-Octyl-5-nitronaphthalimide;

2-{2-(4-Methylbenzylsulphonamido)-4,5-dichlorophenyl}naphthalimide;

3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene;

3-Amino-7,4-bis(ethyl-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and

2-(Benzimidaz-2-yl)-1,3-dioxo-1,2,3,4-tetrahydrobenzo[i]isoquinoline.

A
CONT -

7. A pharmaceutical composition according to claim 1 wherein the compound of Formula I is N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol or its pharmaceutically acceptable salt.

A2
B3
B4

13. An *in vivo* hydrolyzable ester or amide of a compound selected from the group consisting of: N-{5-Nitro-1H-benz[de]isoquinoline-1,3(2H)-dione}-2-aminoethanol; 3-Nitro-1,8-(N-propioncarboxylate)succinamidonaphthalene; 3-Amino-7,4-bis(ethyl-1,3-dioxo)-1,2,3,4-tetrahydrobenzo[i]isoquinoline; and 2-(2-Hydroxyphenyl)naphthalimide.

Please cancel claim 8 without prejudice or disclaimer.

Please add new Claims 14-19 as follows:

New Claims

A3

14. A method of treating pain in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.

15. A method of treating Alzheimer's disease in a mammal comprising the step of administering to said mammal a therapeutically effective amount of a composition as defined in claim 1.